BioInno key facts
as of Oct 2026- Provider of CDMO process development and GMP production services for cell culture, bioprocessing, and biologics-related technical applications.
- BioInno is valued at approximately $156.4M as of Oct 2026 (last reported valuation).
- It has raised $48.1M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Tailong VC, Orient Securities Capital Investment Company, Ciit Asset Management, HJ-Investment — 13 tracked in total.
- Status: Privately Held (backing).
BioInno's last reported valuation, Dec 2021. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch BioInno: the Monday email on marks, rounds and moves
BioInno funding rounds
No funding rounds for BioInno are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs BioInno
13+Membership and data by Private Market View
BioInno valuation
BioInno's last reported valuation was $156 million in Dec 2021. No priced round, secondary trade or fund mark has surfaced since.
BioInno investors
13 investors are on record for BioInno, including Shenzhen Yifeng Investment Management Enterprise, Tailong VC, Orient Securities Capital Investment Company and Ciit Asset Management.
About BioInno
Provider of CDMO process development and GMP production services for cell culture, bioprocessing, and biologics-related technical applications. The company offers outsourcing services, specializing in developing cell therapy and gene therapy drugs for biotechnology and pharmaceutical companies.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Employees
- 4
- Website
- bioinnobio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.